BioSpace News Archive

Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.

A small Phase II study published Wednesday in the New England Journal of Medicine suggests psilocybin, a psychedelic compound found in “magic mushrooms,” may be an effective treatment for moderate-to-severe major depressive disorder.

Several companies launched with Series A financing rounds today. Read on for details.

The medical device maker has been dropping money like rain this spring, spending close to $19 billion in acquisitions over the past four months.

Gynesonics®, a women’s healthcare company focused on the development of minimally invasive solutions for symptomatic uterine fibroids, announced the publication of its peer reviewed journal article, “Transcervical Radiofrequency Ablation of Uterine Fibroids Global Registry (SAGE): Study Protocol and Preliminary Results,” in the journal Medical Devices: Evidence and Research

Joerns Healthcare, LLC, a leading medical equipment services company to the care continuum, announced that they have entered into a sole source agreement with Bristol Hospice, LLC. Joerns Healthcare’s hospice integrated business system was a key value-driver for the agreement.

Cardionomic, Inc., a Minneapolis medical device company, is pleased to announce initial enrollment in their Cardionomic Pulmonary Neuromodulation System (CPNS) Pilot Study.

The European Union Intellectual Property Office declared that U-BioMed’s falsely registered AQUAGOLD® European Union trademark is invalid in its entirety, as it was originally created and owned by Aquavit Pharmaceuticals, Inc.

MedVector announces that it has appointed John Neal, founder and chairman of PCRS Network, as strategic advisor, pharma relations and clinical protocol.

The I-SPY COVID Trial, sponsored by Quantum Leap Healthcare Collaborative (QLHC), was designed to rapidly screen agents that show promise for reducing the time to recovery (defined as reduction in oxygen demand) by approximately 50% or risk of mortality in critically ill COVID-19 patients.